

# UC San Diego

## UC San Diego Previously Published Works

### Title

Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes

### Permalink

<https://escholarship.org/uc/item/8630x108>

### Journal

JCI Insight, 4(3)

### ISSN

2379-3708

### Authors

Koskimäki, Janne  
Girard, Romuald  
Li, Yan  
et al.

### Publication Date

2019-02-07

### DOI

10.1172/jci.insight.126167

Peer reviewed

# Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes

Janne Koskimäki,<sup>1</sup> Romuald Girard,<sup>1</sup> Yan Li,<sup>2</sup> Laleh Saadat,<sup>1</sup> Hussein A. Zeineddine,<sup>1</sup> Rhonda Lightle,<sup>1</sup> Thomas Moore,<sup>1</sup> Seán Lyne,<sup>1</sup> Kenneth Avner,<sup>1</sup> Robert Shenkar,<sup>1</sup> Ying Cao,<sup>1</sup> Changbin Shi,<sup>1</sup> Sean P. Polster,<sup>1</sup> Dongdong Zhang,<sup>1</sup> Julián Carrión-Penagos,<sup>1</sup> Sharbel Romanos,<sup>1</sup> Gregory Fonseca,<sup>3</sup> Miguel A. Lopez-Ramirez,<sup>4</sup> Eric M. Chapman,<sup>5</sup> Evelyn Popiel,<sup>5</sup> Alan T. Tang,<sup>6</sup> Amy Akers,<sup>7</sup> Pieter Faber,<sup>8</sup> Jorge Andrade,<sup>2</sup> Mark Ginsberg,<sup>4</sup> W. Brent Derry,<sup>5,9</sup> Mark L. Kahn,<sup>6</sup> Douglas A. Marchuk,<sup>10</sup> and Issam A. Awad<sup>1</sup>

<sup>1</sup>Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA. <sup>2</sup>Center for Research Informatics, The University of Chicago, Chicago, Illinois, USA. <sup>3</sup>Department of Cellular and Molecular Medicine and <sup>4</sup>Department of Medicine, UCSD, La Jolla, California, USA. <sup>5</sup>Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. <sup>6</sup>Department of Medicine and Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA. <sup>7</sup>Angioma Alliance, Norfolk, Virginia, USA. <sup>8</sup>University of Chicago Genomics Facility, The University of Chicago, Chicago, Illinois, USA. <sup>9</sup>Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada. <sup>10</sup>The Molecular Genetics and Microbiology Department, Duke University Medical Center, Durham, North Carolina, USA.

The purpose of this study was to determine important genes, functions, and networks contributing to the pathobiology of cerebral cavernous malformation (CCM) from transcriptomic analyses across 3 species and 2 disease genotypes. Sequencing of RNA from laser microdissected neurovascular units of 5 human surgically resected CCM lesions, mouse brain microvascular endothelial cells, *Caenorhabditis elegans* with induced *Ccm* gene loss, and their respective controls provided differentially expressed genes (DEGs). DEGs from mouse and *C. elegans* were annotated into human homologous genes. Cross-comparisons of DEGs between species and genotypes, as well as network and gene ontology (GO) enrichment analyses, were performed. Among hundreds of DEGs identified in each model, common genes and 1 GO term (GO:0051656, establishment of organelle localization) were commonly identified across the different species and genotypes. In addition, 24 GO functions were present in 4 of 5 models and were related to cell-to-cell adhesion, neutrophil-mediated immunity, ion transmembrane transporter activity, and responses to oxidative stress. We have provided a comprehensive transcriptome library of CCM disease across species and for the first time to our knowledge in *Ccm1/Krit1* versus *Ccm3/Pdcd10* genotypes. We have provided examples of how results can be used in hypothesis generation or mechanistic confirmatory studies.

**Authorship note:** JK and RG contributed equally to this work.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**License:** Copyright 2019, American Society for Clinical Investigation.

**Submitted:** November 12, 2018

**Accepted:** January 3, 2019

**Published:** February 7, 2019

**Reference information:**

JCI Insight. 2019;4(3):e126167.

<https://doi.org/10.1172/jci.insight.126167>

insight.126167.

## Introduction

Cerebral cavernous malformations (CCMs) are hemorrhagic vascular brain lesions predisposing 0.5% of the worldwide population to a lifetime risk of intracerebral hemorrhage and seizures. CCMs are clusters of caverns lined with endothelium lacking mature blood vessel architecture (1). Two forms of the disease exist, one of which is a sporadic form accounting for 70% of cases manifesting a solitary lesion (2). The familial form is inherited in an autosomal dominant pattern with mutations in 1 of 3 documented genes (*CCM1/KRIT1*, *CCM2/MGC4607*, or *CCM3/PDCD10*) causing multifocal lesions to develop stochastically throughout the brain during the patient's life (2). Familial and sporadic CCMs are histologically indistinguishable and harbor somatic mutations in the same genes, suggesting a common pathological mechanism (3). However, cases with *CCM3/PDCD10* mutations exhibit exceptional disease aggressiveness, the cause of which remains speculative (2).

*CCM* genes encode proteins responsible for maintaining integrity of endothelial permeability by inhibiting RhoA-associated kinase (ROCK) activation (4). Greater ROCK activity leads to dysregulated endothelial junctional proteins resulting in increased blood vessel permeability (4). In addition, in vivo and

in vitro mechanistic studies have reported a complex interplay of angiogenic and inflammatory processes in the genesis and maturation of CCM lesions, including signaling aberrations related to endothelial MEKK3-KLF2/4 signaling (5, 6), angiogenic activity (6–8), antigen-mediated immune response (9), and endothelial-mesenchymal transition (5).

Previous studies on the differential transcriptome of resected CCM lesions were performed on the whole lesional tissue, which includes many cell types (10, 11). However, experimental evidence supports that CCM physiopathology arises primarily in endothelium (5, 12). In addition, it is clear that CCM3 engages distinct signaling pathways from CCM1/CCM2, yet patients with mutations in any of the 3 genes develop the same lesions, suggesting that they likely converge on similar biological processes. Therefore, it is important to specifically study the transcriptomic differences between in vivo and in vitro lesional endothelial cells (ECs) and between different genotypes. *Caenorhabditis elegans* has a well-characterized genome but lacks a circulatory system, yet it manifests a discrete phenotype with *Ccm* homologous gene loss (13, 14). Recently, Lant and coworkers conducted a genome-wide RNA interference screen that uncovered several genes with human homologs that induced a CCM-like phenotype in *C. elegans* (13). The remarkable conservation of CCM gene function from nematode to human prompted us to ask if we could construct a refined network by systematically analyzing DEGs across species and genotypes.

Herein, we leveraged models and data from different laboratories, to cross-compare the differentially expressed genes (DEGs), their networks, their pathways, and their functions in human neurovascular units (NVUs) from surgically resected lesions, and with the induced loss of 2 disease genes (*Ccm1/Krit1* and *Ccm3/Pcd10*) in cultured mouse brain microvascular endothelial cells (BMECs) and in *C. elegans*. We hypothesized that common DEGs across species may reflect conserved and important pathological processes relevant in the human disease. We also postulated that DEGs between the 2 different genotypes in mouse BMEC and *C. elegans* models would reflect differences in disease manifestations and aggressiveness.

## Results

*DEGs and gene ontologies in lesional human NVUs, mouse BMECs, and C. elegans.* After sequencing, 915 DEGs (fold change [FC]  $\geq 1.2$ ;  $P < 0.05$ , FDR corrected) were identified in human microdissected lesional NVUs compared with normal control capillaries (Supplemental Figure 2A; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.126167DS1>). In addition, the individual expression profile for each patient (Supplemental Figure 3) suggests a downregulation of at least 1 of the *CCM* genes (*CCM1*, *CCM2*, and *CCM3*) in the microdissected lesional NVUs.

In mouse BMECs, 1,932 and 524 DEGs (FC  $\geq 1.2$ ;  $P < 0.05$ , FDR corrected) were observed in *Ccm1/Krit1*<sup>ECKO</sup> and *Ccm3/Pcd10*<sup>ECKO</sup>, respectively (Supplemental Figure 2, B and D). In *C. elegans ccm1/kri-1* and *ccm3/pcd10* mutants, 1,643 and 1,581 DEGs (FC  $\geq 1.2$ ;  $P < 0.05$ , FDR corrected) were identified, respectively (Supplemental Figure 2, C and E).

Further analyses showed that 1,307 gene ontology (GO) terms ( $P < 0.1$ , FDR corrected) were overrepresented in human lesional NVUs (Figure 1A), 1,565 GO terms in *Ccm1/Krit1*<sup>ECKO</sup> BMECs, 283 GO terms in *Ccm3/Pcd10*<sup>ECKO</sup> BMECs (Figure 1, B and D), 519 GO terms in *C. elegans ccm1/kri-1* and 685 GO terms in *ccm3/pcd10* (Figure 1, C and E). The GO analyses in the human NVUs reflected neuronal as well vascular processes. The GO analyses across the different species and genotypes revealed functions related to angiogenesis, inflammation, immune cell activity, junctional adhesion, intracellular organelle localization, extracellular matrix and structure remodeling, serine/threonine kinase activity, and apoptosis. One GO term (GO:0051656, establishment of organelle localization) was commonly identified across the different species and genotypes. In addition, 24 GO functions were present in 4 out of 5 models and were related to cell-to-cell adhesion, neutrophil-mediated immunity, ion transmembrane transporter activity, and responses to oxidative stress (Supplemental Figure 4).

*Network and GO analysis of DEGs in human CCM lesions.* Sixteen genes were highly connected (with at least 20 edges) in the gene network defined for the 915 DEGs identified in the human microdissected lesional NVUs (Figure 2). Among these 16 genes, 4 were related to the expression of integrin subunits, *ITGA4*, *ITGB5*, *ITGB2*, and *ITGAM*, and 1 to the expression of fibronectin (*FNI*). Three genes, namely *PLCB2*, *PIK3CG*, and *PIK3R5*, belong to the phosphatidylinositol pathway. *PTK2* was also part of this highly connected network and encodes for a focal adhesion kinase (FAK) that is directly related to cell adhesion (15). Furthermore, *PRKCB*, which belongs to a protein kinase C family; *VAMP2*, which produces vesicle-associated proteins (16); *GNAO1*, which encodes an  $\alpha$  subunit of the G<sub>o</sub> protein abundant

in the CNS and promotes oncogenesis and TLR signaling (17, 18); *DLG4*, which encodes postsynaptic density protein 95 and belongs to a membrane-associated guanylate kinase family; and lymphocyte-specific protein kinase were all also identified in this highly connected human network. Finally, 2 other genes were also present in this highly connected network, including *CALM1*, which encodes for calmodulin 1 with an established role in cellular growth and neurotransmitter production and release (19), and *TFAP2A*, which codes for the transcription factor AP-2 $\alpha$ .

We identified 95 enriched GO terms ( $P < 0.01$ , FDR corrected) using the 16 genes with more than 20 edges. The results showed defined enriched functions related to extracellular matrix processes, cellular adhesion, integrin processes, blood vessel morphogenesis, the phosphatidylinositol pathway, the TLR4 signaling pathway, vesicle transportation, and metal ion transportation (Supplemental Table 4).

*Common DEGs and gene networks among human NVUs, mouse BMECs, and C. elegans.* *SPARCL1*, *PDGFRFA*, *FAXC*, and *UNC13A* ( $FC \geq 1.2$ ;  $P < 0.05$ , FDR corrected for all) were common between human lesional NVUs and *Ccm1/Krit1* models of both the mouse BMECs and *C. elegans*. We then considered loosening the  $P$  value threshold for *C. elegans* ( $P < 0.25$ , FDR corrected) to correct unbalanced restriction in analyses because only 17% of *C. elegans* genes have corresponding human gene homologs. We then identified 4 additional common DEGs, namely *FAT1*, *PLXDC2*, *PLCD3*, and *GNAO1*, in both *Ccm1/Krit1* models, mouse BMECs, and *C. elegans*, as well as human lesional NVUs (Supplemental Figure 5). *FAT1* was also found to be commonly differentially expressed in human NVUs and in *Ccm3/Pdcd10* mouse BMECs and *Ccm3/Pdcd10 C. elegans* (Figure 3, A and B). *PLCD3*, *FAT1*, *GNAO1*, *PDGFRFA*, and *SPARCL1* were identified in the Reactome FIViz database (Figure 3B).

Further analyses between mouse BMEC models, regardless of the genotype, and human microdissected lesional NVUs identified 36 common DEGs (Supplemental Figure 6 and Supplemental Table 5). In addition, 10 and 109 genes were commonly differentially expressed between human microdissected lesional NVUs and *Ccm3/Pdcd10<sup>ECKO</sup>* and *Ccm1/Krit1<sup>ECKO</sup>*, respectively.


*DEGs, enriched GOs, and gene networks of Ccm1/Krit1 and Ccm3/Pdcd10 genotypes.* We finally assessed the unique DEGs of each genotype for *Ccm1/Krit1* and *Ccm3/Pdcd10* in mouse BMEC and *C. elegans* models ( $FC \geq 1.2$ ;  $P < 0.05$ , FDR corrected). We identified 1,541 DEGs only in *Ccm1/Krit1<sup>ECKO</sup>* BMECs, and 195 in *Ccm3/Pdcd10<sup>ECKO</sup>* BMECs, without comparison to other models. In *C. elegans* models alone, 676 DEGs were found only in *ccm1/krit-1* and 656 only in *ccm3/pdcd10*. Finally, 71 DEGs were commonly identified only in *Ccm1/Krit1*-mutant models and 11 only in *Ccm3/Pdcd10* using comparisons across the murine and worm models (Supplemental Tables 6 and 7). Notably, we observed that both genotypes showed differential expression of their respective knockout genes, *Ccm1/Krit1* and *Ccm3/Pdcd10* (Supplemental Tables 2 and 8).

Further analyses identified 14 and 247 ( $P < 0.1$ , FDR corrected) enriched GO terms in *Ccm1/Krit1* and *Ccm3/Pdcd10* genotypes, respectively (Supplemental Tables 9 and 10). *Ccm1/Krit1* genotype GO functions were primarily related to DNA repair, angiogenesis, microtubule function, and magnesium ion binding (Figure 4A). *Ccm3/Pdcd10* genotype showed fundamental functions for rRNA processing, ribosome biogenesis and its structural components, protein targeting to endoplasmic reticulum, protein intracellular targeting, and vesicle transportation to a cell membrane (Figure 4B).

Gene network analyses were performed separately for *Ccm1/Krit1* and *Ccm3/Pdcd10* (Figure 5). In *Ccm1/Krit1*, 6 genes with more than 6 edges were identified: *FGFR3*, *PDGFRFA*, *PLK1*, *RFC2*, *NUP85*, and *PLCD3*. In the *Ccm3/Pdcd10* model, only *RPL21* and *RPS18* had more than 6 edges.

## Discussion

The loss of all 3 known CCM genes in endothelium is embryonically lethal in mammals (12, 20), hence highlighting the fundamental biological role of these genes and associated networks and pathways. We here cross-compared the transcriptomic profiles of human resected lesional NVUs, and 2 genotypes, *Ccm1/Krit1* and *Ccm3/Pdcd10*, in both mouse BMECs and *C. elegans*. The 3 respective models reflected differential transcriptomes of human lesional endothelium and its adjacent milieu and the impact of *Ccm* gene loss in cultured BMECs as well as in a whole organism. We aimed to identify conserved genes, GO functions, and related networks across these models and those associated commonly or uniquely in *Ccm1/Krit1* and *Ccm3/Pdcd10* genotypes. Some of the results validate previously published mechanistic links, while others shed new light on disease pathobiology. The data presented herein will be useful to the research community in querying and validating potential mechanistic, biomarker, and therapeutic targets.




**Figure 1. Top 18 GO functions of DEGs for each species by genotype.** The gene set enrichment analyses ( $P < 0.1$  for all, FDR corrected) identified (A) 1,307 GO terms in human lesional NVUs, (B) 1,565 in *Ccm1/Krit1*<sup>ECKO</sup> BMECs, (C) 519 in *C. elegans* with a *ccm1/kri-1* mutation, (D) 283 in *Ccm3/Pdcd10*<sup>ECKO</sup> BMECs, and (E) 685 in *C. elegans ccm3/pdcd10*. The DEGs were defined as FC greater than or equal to 1.2, with  $P$  less than 0.05 (FDR corrected), for all the models. For display purposes, only the top GOs are presented in each category (BP, MF, and CC) by their respective proportion. BP, biological processes; MF, molecular functions; CC, cellular components; ncRNA, noncoding RNA; and SRP, signal recognition particle. Gene ratio is reported at the end of each respective GO.

*The transcriptome profile of the human microdissected lesional NVUs.* The transcriptome profile of the human lesional microdissected NVUs showed 16 highly connected (more than 20 edges) genes. From those genes, *GNAO1* was also identified in 2 models: mouse BMEC *Ccm1/Krit1*<sup>ECKO</sup> and *C. elegans ccm1/kri-1*. *GNAO1* encodes an  $\alpha$  subunit of the  $G_o$  ( $G_{\alpha o}$ ) protein that is abundant in the CNS (17). A mutation of *GNAO1* has been shown to promote cellular transformation and oncogenic signaling (18). Similarly, a mutation in *GNAQ*, a  $G_{\alpha q}$  protein-coding gene, has been reported to cause constitutive subunit activation by attenuating GTPase activity of the  $\alpha$  subunit (20). A greater number of ECs with mutations on *GNAQ* has been shown to be associated with neurovascular disorders, including capillary malformations, Sturge-Weber syndrome, as well as port-wine stains (21, 22). *GNAO1* has also been associated with TLR2 receptor downstream signaling (17). TLR2 receptor has been found to be the key molecular sensor for oxidative stress that links oxidative stress, inflammation, innate immunity, and angiogenesis (23). In addition, maturation of CCM lesions has been recently associated with TLR4, signaling which activates the same pathways as TLR2, although the ligands may be different (24).

*PIK3CG*, *PIK3R5*, and *PLCB2* were also identified to be highly connected in the human DEG network. Phosphoinositide 3-kinase (PI3K) proteins were shown to be involved in vascular disease (20). They are activated through G protein-coupled receptors and tyrosine kinase receptors. Particularly, *PIK3CG*






**Figure 2. Focused functional interaction network of DEGs in human lesional NVUs.** A total of 915 DEGs ( $FC \geq 1.2$ ;  $P < 0.05$ , FDR corrected) were identified in human lesional NVUs and used to generate a gene network. Sixteen DEGs were identified with more than 20 edges. Among these highly connected DEGs, the *GNAO1* was also conserved in BMECs of *Ccm1/Krit1<sup>ECKO</sup>* and *C. elegans ccm1/kri-1*.

is a catalytic subunit of class I PI3Ks that produces phosphatidylinositol (3,4)-biphosphate (PtdIns[3,4]P<sub>2</sub>), phosphatidylinositol(3,4,5)-triphosphate (PIP<sub>3</sub>), as well as phosphatidylinositol 3-phosphate (PI3P). PIK3R5 protein belongs to a group of class I PI3Ks functioning as a regulatory subunit for PI3Ks. Phospholipase C  $\beta 2$  (PLCB2) is also activated by G protein-coupled receptor signaling, and PLCB2 protein catalyzes PIP<sub>2</sub> breakdown to inositol triphosphate (IP3) and diacylglycerol. Previous work has shown that venous and capillary malformations are associated with mutations of the *PIK3CA* (20). This gene belongs to the same class of PI3Ks as the *PIK3CG* gene that is identified to be highly connected in the network. PIK3CA acts as a catalytic subunit for PI3Ks, similar to PIK3CG, inducing phosphorylation of downstream signaling of phosphoinositides. This pathway activates responses related to growth, proliferation, cell survival, and angiogenesis. There is also strong evidence from mouse models supporting a role of the PI3K subunit in the regulation of angiogenesis and activation of RhoA GTPase that contribute to CCM lesion progression (12, 20).

Four genes coding integrin subunits *ITGA4*, *ITGB5*, *ITGB2*, and *ITGAM* were also highly connected in the human network. Previous studies have reported the importance of integrins, cadherins, and tight junctions in the maintenance of vascular integrity (1). The dysregulation of CCM proteins affects integrin  $\beta_1$ -KLF2 activity, which mediates angiogenesis, suggesting a role of integrins as downstream signaling proteins (6).




**Figure 3. Common genes conserved across species.** (A) Eight DEGs were commonly identified in human lesional NVUs, both *Ccm1/Krit1<sup>TECKO</sup>* and *Ccm3/Pdcd10<sup>ECKO</sup>* mouse BMECs, and both *ccm1/kri-1* and *ccm3/pdcd10* *C. elegans* models (FC  $\geq 1.2$ ;  $P < 0.05$ , FDR corrected for human and both genotypes of mouse BMECs. FC  $\geq 1.2$ ;  $P < 0.25$ , FDR corrected for both genotypes of *C. elegans*). Functions of the DEGs were related to antiangiogenesis, cell growth, vesicle exocytosis, axon development, G protein-coupled signaling and oncogenesis. Red indicates an increased FC and blue a decreased FC. (B) The focused protein functional interaction network analysis identified 5 of the 8 common DEGs: *PLCD3*, *FAT1*, *GNAO1*, *PDGFRA*, and *PLCD3*. *PLCD3* is linked with *PIK3CA* directly but also via *PTEN* that inhibits *PIK3CA*. *SPARCL1* is associated with *AKT3* that activates *PIK3CA*. *GNAO1* is linked to *VEGF* that activates *PDGFRA* that further activates *PIK3CA*. Interestingly, *FAT1* is linked to *PCDHGA11* that receives activation from *EP300*. *EP300* further activates *VEGF* and *PDGFRA*, creating bidirectional activation for *PDGFRA* that in turn activates *PIK3CA*.

Previous studies in cultured ECs suggest that vascular endothelial growth factor A (VEGF-A) stimulates phosphorylation and recruitment of focal adhesions (15). Recently our group has also shown that VEGF-A levels are altered in plasma of CCM patients (7). In addition, a recent article demonstrated a circuitous role for *IL-7*, *CXCR4*, and *FAK* in B cell development (25). Interestingly, B cell depletion treatments have been shown to blunt lesion burden and hemorrhage in murine models of CCM disease (9). The present study showed upregulation of the *IL7R* and *CXCR4* genes, as well as downregulation and high connectivity of the *PTK2* gene, which codes for *FAK* and is also connected to *ITGB5* in our human network. Further mechanistic studies are needed to define the complex role of junctional proteins in CCM disease in further detail.

Fibronectin (*FNI*) was also a highly connected gene in the human network analysis. Fibronectin has been reported to be involved during the early stages of the coagulation process when endothelium is injured and becomes an antithrombotic agent during the latest stages (26). In addition, our previous studies in vivo have suggested that thrombospondin-1, a natural antiangiogenic protein related to the blood coagulation cascade, affects CCM lesion progression (8). In light of these results, the role of fibronectin in CCM lesion pathogenesis should be studied in greater detail.

*The common transcriptome profile among human microdissected lesional NVUs, BMECs, and C. elegans.* The cross-comparison of the transcriptomes between the human lesional NVUs and 4 different models identified the *FAT1* gene was conserved across the species and genotypes. *FAT1* is a protocadherin associated with the hippo pathway and has been shown to regulate cell proliferation, apoptosis, cell polarization, and cell-to-cell adhesion (27). In addition, *FAT1* has modulatory activity to  $\beta$ -catenin in vascular smooth muscle cells as it also stabilizes the CCM complex in ECs in *Ccm1/Krit1* disease models (27, 28). However, its role in CCM pathogenesis remains unclear.

Seven additional genes (*UNC13A*, *SPARCL1*, *PDGFRA*, *GNAO1*, *PLCD3*, *FAXC*, and *PLXDC2*) were commonly identified in human lesional NVUs and *Ccm1/Krit1* genotypes of both BMECs and *C. elegans*. In normal ECs from the brain of *Ccm3/Pdcd10* mice, an inhibition of *Unc13b*, a paralog of *Unc13a*, and *Vamp3* through *Ccm3* protein is associated with a decrease in angiopoietin-2 exocytosis (16). Thus, a loss of the *Ccm3/Pdcd10* gene increases exocytosis of angiopoietin-2 (16). These pathophysiological processes are associated with a wide range of EC dysfunction promoting CCM disease progression (16). In addition, *Vamp2*, an important




**Figure 4. Top GO functions unique to either *Ccm1/Krit1* or *Ccm3/Pdcd10* genotypes. (A)** A total of 71 DEGs were identified only in the *Ccm1/Krit1* genotype in both mouse BMECs and *C. elegans*. The gene set enrichment analyses showed 14 enriched GO terms ( $P < 0.1$ , FDR corrected) in *Ccm1/Krit1* related to DNA repair, angiogenesis, microtubule functions, and magnesium ion binding. **(B)** Eleven DEGs were identified only in the *Ccm3/Pdcd10* genotype and were associated with 247 GO functions. The top 18 GO terms were related to fundamental functions for rRNA processing, ribosome biogenesis and structural constituents, protein targeting to endoplasmic reticulum, protein intracellular targeting, and vesicle transportation to a cell membrane. The DEGs were defined as  $FC \geq 1.2$  and  $P < 0.05$  (FDR corrected). BH, Bcl-2 homology. Gene ratio is reported at the end of each respective GO.

paralog of *Vamp3*, was identified to be highly connected in the human lesional NVUs network. These results suggest a role of vesicle transportation in the physiopathology of CCM disease, which is supported by observations in *C. elegans* showing that *ccm3* promotes *Cdc42* activity and endocytic recycling (14).

The 5 DEGs (*SPARCL1*, *PLCD3*, *PDGFRA*, *PLXDC2*, and *FAXC*) that were common among human lesional NVUs and the *Ccm1/Krit1* genotypes of both BMECs and *C. elegans* do not currently have postulated functions in CCM disease. However, *SPARCL1* and *PLCD3* have been associated with cellular proliferation, migration, and cancer (29, 30). *PLCD3* belongs to a phospholipase C family and may be linked to the phosphatidylinositol signaling pathway (30). *PDGFRA* is a growth factor also related to cellular growth, differentiation, and tumor vasculogenesis (31). Interestingly, *PLXDC2* relays antiangiogenic signaling of pigment epithelium-derived factor (PEDF, *SERPINF1*) (32). Hypoxic conditions have been shown to downregulate antiangiogenic activity of PEDF (32).





**Figure 5. Functional interaction network of DEGs conserved in both mouse BMECs and *C. elegans* unique to either *Ccm1/Krit1* or *Ccm3/Pdcd10*.** (A) The functional interaction network analysis of the 71 common DEGs ( $FC \geq 1.2$ ;  $P < 0.05$ , FDR corrected) identified only in *Ccm1/Krit1* models showed that *FGFR3*, *PDGFRA*, *PLK1*, *NUP85*, and *PLCD3* had more than 6 edges. (B) The functional interaction network analysis of the 11 common DEGs ( $FC \geq 1.2$ ;  $P < 0.05$ , FDR corrected) identified only in the *Ccm3/Pdcd10* genotype revealed that *RPL21* and *RPS18* were the genes with the most edges (more than 6).

Last, *FAXC* is mainly expressed in axon bundles and related to axon development (33). Its role in CCM remains unclear but may reflect a role of the whole NVU and neuronal environment in CCM physiopathogenesis. Interestingly, deletion of *ccm3/pdcd10* in glia can induce lesion formation in the neural vasculature of mice (34).

These 8 genes provide potentially novel information of a conserved part of CCM physiopathogenesis and highlight commonalities between disease models and human lesions, providing strong candidate genes for further mechanistic studies. Finally, the common GO terms across the species reflected current knowledge on CCM physiopathogenesis.

*Unique transcriptome profiles of Ccm1 versus Ccm3.* The different genotypes in CCM disease have important implications regarding clinical outcomes. Patients with the *CCM3* genotype show earlier onset, higher lesion burden, and an increased risk of bleeding compared with patients harboring the *CCM1* mutation (2). These physiopathological and phenotypic differences observed between *CCM1* and *CCM3* genotypes may be explained at the transcriptomic level.

In *Ccm1/Krit1*, 6 DEGs with more than 6 edges, namely *FGFR3*, *PDGFRA*, *RFC2*, *PLK1*, *NUP85*, and *PLCD3*, were identified. *FGFR3* relays cell growth and angiogenesis signals and is broadly associated with tumorigenesis (31). *PDGFRA* is a growth factor receptor for platelet-derived growth factor that supports cellular growth, survival, and proliferation (31). *RFC2* also promotes cell survival by regulating cell cycle progression from G1 to S phase (35). Interestingly, *PLK1* takes part in the cell cycle, controlling progression from G2 to M phase, and is considered a protooncogene (36). *NUP85* was also only identified in *Ccm1/Krit1*. It is a subunit of the Nup107-160 complex responsible for formation of normal nuclear pores and is required for mitotic spindle assembly during mitosis (37). A dysregulation of this complex causes deficits in transportation of macromolecules, such as RNA, across the nucleus and cytoplasm (37).

The GO analyses of unique genes for *Ccm1/Krit1* were related to DNA repair, angiogenesis, microtubule functions, and magnesium ion binding. Mitotic spindle formation and macromolecule transportation across the nucleus and cytoplasm are important steps in cell cycle control (36). Our results suggest that a dysregulation of the cell cycle control may be an important process in the *Ccm1/Krit1* genotype that may explain the differences between the 2 phenotypes.

In the *Ccm3/Pdcd10* model, *RPL21* and *RPS18* were highly connected (more than 6 edges) and were also connected with *KRAS*, which linked *Ccm3/Pdcd10* to the rest of the network. *RPL21* encodes a protein component for ribosome 60S subunit, and *RPS18* encodes a component for ribosome 40S subunit (38). In addition, recent evidence shows that *RPL29*, a component of ribosome 60S subunit, is involved in angiogenesis processes (39). A dysfunction of *RPL29* affects the integrins of ECs (39). These results may suggest a role of ribosomal dysfunction in CCM physiopathogenesis.

Furthermore, *SNX2*, *ALDH4A1*, *COL4A3BP*, and *DNM1L* observed only in *Ccm3/Pdcd10* are related to apoptosis, ROS signaling, and intracellular endosome trafficking (40–43). *SNX2* is linked to intracellular trafficking–sensing membrane curvature and interacts with phosphoinositols PI3P and PtdIns(3,5)P<sub>2</sub> in earlier stages of the formation of the endosomes (41). *ALDH4A1* codes for a mitochondrial NAD-dependent hydrogenase involved in proline metabolism that maintains important balance of mitochondrial ROS (40). *COL4A3BP* regulates ceramide transportation from endoplasmic reticulum (42). A dysregulation of this gene causes ceramide accumulation in mitochondria, inducing Bax-dependent apoptosis (42). Interestingly, *C. elegans* with *ccm1/kri-1* mutation are resistant to stress-induced apoptosis (44), suggesting a role for cell death in the pathobiology of CCM. Finally, *DNM1L* is involved in numerous functions in mitochondria. Its dysregulation causes increased production of ROS, mutations of DNA regulation, as well as dysfunctions in mitochondrial fission and fusion (43).

The enriched GO functions in *Ccm3/Pdcd10*-specific genes were related to rRNA processing, ribosome biogenesis and structural constituents, protein targeting to endoplasmic reticulum, protein intracellular targeting, and vesicle transportation to a cell membrane. Defects in vesicle transportation and protein intracellular targeting are well-established features in the *Ccm3* genotype (13, 14, 16, 45). However, suggested GO functions related to rRNA processing and functioning are not yet understood and may reflect defects in protein construction.

The genes dysregulated in *Ccm1/Krit1* genotype are associated with functions of cell cycle control, growth, and proliferation. In contrast, in *Ccm3/Pdcd10* the dysregulated genes are associated with apoptosis, ROS metabolism, and intracellular vesicle trafficking. Ribosomal dysfunction in human disease is an interesting concept that remains to be established with the appropriate models. These results provide conserved candidate genes for interrogation that are unique for either genotype in mouse BMECs and *C. elegans* CCM disease models.

*Use of transcriptome library to support molecular mechanisms in CCM disease.* Our transcriptome library provides a database to query DEGs in human lesional NVUs and 2 widely used genetically engineered animal models of CCM disease. Transcriptome data of human lesional NVUs have already been used to support mechanistic findings in animal models, allowing the identification of potential biomarkers to be used in CCM patients (8). Indeed, we have recently reported that loss of brain endothelial thrombospondin-1 (*TSP1*) in murine *Ccm1/Krit1<sup>ECKO</sup>* has been shown to contribute to CCM pathogenesis (8), which is consistent with the downregulation of *TSP1* in human lesional NVUs.

*Limitations.* It is important to acknowledge the limitations of our study. First, we defined a common FC threshold ( $\geq 1.2$ ) to identify the DEGs for all the different models studied. A lower FC threshold applied to RNA-Seq results can increase the false positive discovery. We used an arbitrary FC threshold to allow the comparisons between different experimental designs. In addition, low expressed genes are usually hard to detect. However, we performed a rigorous FDR correction, rather than using the nominal *P* value, thus decreasing the possibility of false positive discovery in our results. In addition, different databases can be used during the different steps of the analyses and may give slightly different results. Here we used the well-established open-source GO database based on hypergeometric test and Cytoscape with ReactomeFIViz module.

For RNA-Seq analysis, the sequencing depth is another concern. Even though different sequencing depth has been normalized in DEG identification analysis, sequencing depth or library size difference between different species because of samples' RNA extraction difficulty might be severer in comparison with a study within the same species. The DEG analyses are conducted based on the statistical model. Statistical analysis by itself has its own statistical power to identify DEGs in a small sample size. In addition, when comparing different species' identified DEGs, the homologous genes between mouse BMECs and *C. elegans* and humans relies on the homologous genes database. Thus definition of homologous genes between species also needs to be understood. Furthermore, gene comparison of DEGs between species were based solely on the homology of the genes. This explains how FCs of some common genes are observed in the opposite direction (Supplemental Tables 6 and 7). The phenomenon may be due to fundamental differences in models used. Mouse BMECs are specifically ECs, while *C. elegans* is a whole organism with multiple cell types.

We acknowledge the technical limitations of laser capture microdissection to isolate pure capillary ECs from lesions. Our differential transcriptome in humans may be composed of cell material from the extremely close vicinity of ECs. However, the DEGs observed in the lesional human NVUs seem to reflect an

EC expression profile strongly (Supplemental Results). In addition, the comparison between the DEGs in human lesional NVUs, mouse BMECs, and *C. elegans* highlights dysregulated genes specifically expressed in ECs of CCM lesions.

The inclusion of *C. elegans* results in this study adds a cross-species perspective of analyzing transcriptomic data and in a whole organism. But because only 17% of *C. elegans* genes have currently corresponding human gene homologs, the ability to perform shared DEG analyses between mammals and *C. elegans* is limited. In addition, *C. elegans* does not have ECs. Although *C. elegans* with a *ccm3/pdcd10* mutation exhibits phenotypes in tube development within stress fiber formation and defects in cell-to-cell contacts, there are other phenotypes apparently unrelated to CCM disease, and the *ccm1/kri-1*-mutated organisms do not seem to exhibit a CCM-like phenotype. Thus, addition of *C. elegans* data may exclude some key genes involved in CCM pathogenesis while it may narrow down the number of key genes.

We used human lesional microdissected NVUs from mostly sporadic lesions as opposed to familial CCMs with specific germline mutations. Although all CCM lesions likely share common pathway-related signaling aberrations (20), we could not distinguish how the different genotypes might contribute to the human lesional transcriptome results. Although the human lesion transcriptomic libraries allow exploratory comparisons with DEGs in different genotypes and organisms, we would be cautious about drawing further conclusions from individual lesion transcriptomes (Supplemental Figure 3). We also did not use a model of *Ccm2* disease for this study. In addition, some studies suggested that the lesional in vivo microenvironment may influence the CCM physiopathogenesis, which is consistent with observations implicating cell-nonautonomous mechanisms for CCM proteins (34, 44). Furthermore, phenotypic differences between engineered animal models suggest that these models recapitulate different features of the development and maturation of CCM lesions (1). We plan to address these gaps by comparing transcriptomes of in vivo microdissected NVUs from murine lesions in comparison with those derived herein by in vitro BMEC gene loss. And we plan to analyze the transcriptome from NVUs of human and murine lesions with various genotypes and from human lesional NVUs with and without recent symptomatic hemorrhage, a clinically relevant disease feature. Finally, our study did not address the effect of loss of CCM gene function in epithelium and other cells (46), which may play secondary roles in disease development, such as influencing gut permeability, which in turn may drive disease development (24). Certainly, our study does not provide direct confirmation of the mechanistic primacy of various DEGs or networks.

**Conclusions.** We provide a unique transcriptome library of CCM disease in human lesional NVUs and in 2 genotypes, *Ccm1/Krit1* and *Ccm3/Pdcd10*, of 2 animal models. Our results suggest important conserved genes with a role in G protein-coupled signaling associated with the phosphoinositol pathway, integrin-related signaling, and vesicle transportation. For the first time to our knowledge, we also provide fundamental transcriptomic differences between *Ccm1/Krit1* and *Ccm3/Pdcd10* genotypes in 2 disease models. Our results validate previously postulated mechanisms and can be used to generate novel hypotheses to gain a greater understanding of CCM disease, its biomarkers, and its therapeutic targeting.

## Methods

Supplemental Methods are available online with this article.

**Laser-captured NVUs of human surgically resected CCM lesions and normal brain capillaries.** Five surgically resected human CCM lesions (Supplemental Table 1 and Supplemental Figure 7) were embedded in optimal cutting temperature, snap-frozen, and stored at  $-80^{\circ}\text{C}$ . Normal brain tissue from 3 subjects free of neurological disease was acquired during autopsy, fixed in formalin, and embedded in paraffin blocks. We mounted 5- $\mu\text{m}$  tissue sections on Leica glass slides (Leica Biosystems Inc) and stained them with HistoGene (Applied Biosystems) for frozen tissue and with Paradise stain (Applied Biosystems) for paraffin-embedded tissue, according to the manufacturers' protocols. The endothelial layer, including adjacent luminal and extraluminal elements (NVUs) from CCMs and normal brain capillaries, were then collected using laser capture microdissection and stored at  $-80^{\circ}\text{C}$  (supplemental material).

RNA was extracted using an RNA isolation kit (RNeasy Micro Kit, Qiagen). cDNA libraries were generated using commercial low-input strand-specific RNA-Seq kits (Clontech) and sequenced on the Illumina HiSeq 4000 platform using single-end 50-bp reads.

***Ccm1/Krit1*<sup>ECKO</sup> and *Ccm3/Pdcd10*<sup>ECKO</sup> BMEC and corresponding wild-type controls.** Adult male and female 2- to 4-month-old mice were used for isolation and purification of primary BMECs. All experiments were performed using the same C57BL/6 background. We generated 3 endothelial-specific conditional *Ccm1/*

*Krit1*-null mice (*Ccm1/Krit1<sup>ECKO</sup>*) using a *Pdgfb* promoter-driven, tamoxifen-inducible Cre recombinase, *Pdgfb-iCreERT2*; *Krit1<sup>fl/fl</sup>* (8). We also generated 3 endothelial-specific conditional *Ccm3/Pdcd10*-null mice (*Ccm3/Pdcd10<sup>ECKO</sup>*) using a *Pdgfb* promoter-driven tamoxifen-inducible Cre recombinase, *Pdgfb-iCreERT2*; *Pdcd10<sup>fl/fl</sup>* (8). BMECs were isolated and purified following a previously described protocol (8). Following purification, BMECs were treated using 5  $\mu$ M 4-hydroxytamoxifen for 48 hours to induce allelic loss in ECs harboring the Cre recombinase-flxed allelic system (8). We chose to add tamoxifen to cultured cells, to insure full gene knockout, rather than speculate about the efficiency of gene deletion in vivo. After 48 hours, the medium was replaced with medium lacking 4-hydroxytamoxifen, and BMECs were harvested in culture after 72 hours for *Ccm1/Krit1<sup>ECKO</sup>* and 168 hours for *Ccm3/Pdcd10<sup>ECKO</sup>*. We performed genome-wide RNA-Seq to detect a decrease of greater than 90% of *Ccm1/Krit1* or *Ccm3/Pdcd10* mRNA after the initial 4-hydroxytamoxifen treatment. After 5 days, a decrease of greater than 90% of *Ccm1/Krit1* mRNA was observed in *Ccm1/Krit1<sup>ECKO</sup>* BMECs but not for *Ccm3/Pdcd10* mRNA in *Ccm3/Pdcd10<sup>ECKO</sup>* BMECs. The decrease of greater than 90% was reached after 9 days for *Ccm3/Pdcd10* mRNA in *Ccm3/Pdcd10<sup>ECKO</sup>* BMECs. For each genotype (*Ccm1/Krit1<sup>fl/fl</sup>* and *Ccm3/Pdcd10<sup>fl/fl</sup>*), 3 control mice were similarly treated with 5  $\mu$ M 4-hydroxytamoxifen.

RNA was extracted using the TRIzol protocol (Thermo Fisher Scientific). TruSeq Stranded mRNA Sample Prep Kit (Illumina) was used for library generation. RNA samples were sequenced using 1-yield single-end 100-bp reads for *Ccm1/Krit1<sup>ECKO</sup>* and 1-yield single-end 75-bp reads for *Ccm3/Pdcd10<sup>ECKO</sup>*.

*Ccm1/kri-1* and *ccm3/pdcd10* *C. elegans* and corresponding wild-type controls. We used 3 biological replicates of *C. elegans* *ccm1/kri-1(ok1251)*-knockout and *ccm3/pdcd10(tm2806)*-knockout mutants to isolate total RNA for sequencing. Wild-type *C. elegans* (N2) were used as controls. Both *C. elegans* models and controls were harvested 24 hours past the L4 state (young adults). RNA was extracted using the TRIzol protocol (Thermo Fisher Scientific). TruSeq Stranded mRNA Sample Prep Kit (Illumina) was used for library generation. RNA samples were sequenced using 1-yield single-end 50-bp reads.

**Statistics.** Bioinformatics analyses and study flow (Supplemental Figure 1) are described in detail in supplemental material. Source data, including full lists of DEGs of human NVUs, mouse BMECs (*Ccm1/Krit1<sup>ECKO</sup>*, *Ccm3/Pdcd10<sup>ECKO</sup>*), and *C. elegans* (*ccm1/kri-1*, *ccm3/pdcd10*) as well as corresponding GO analyses, are presented in detail in supplemental material (Supplemental Tables 2 and 3). The raw sequencing data used in this study are available in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database and is accessible through GEO series accession number GSE123968.

**Study approval.** All patients enrolled in the study gave written informed consent approved by the University of Chicago Institutional Review Board (protocol number 10-295-A). The Declaration of Helsinki and its amendments were followed. The ethical principles guiding the institutional review board are consistent with the *Belmont Report* and comply with the rules and regulations of the Federal Policy for the Protection of Human Subjects (56 FR 28003). All mice experiments were performed in compliance with animal procedure protocols and approved by Institutional Animal Care and Use Committees at the UCSD.

## Author contributions

Studies were designed and conducted by IAA, JK, RG, LS, HAZ, RL, TM, SL, KA, RS, CS, SPP, DZ, JCP, SR, MALR, EMC, EP, ATT, AA, MG, WBD, MLK, and DAM. Samples were sequenced and analyzed by GF, YL, PF, JA, and YC. Results of the study were interpreted and the paper was written by JK, RG, RS, and IAA. The paper was edited by all authors, and all the authors approved the final manuscript.

## Acknowledgments

This work was partially supported by grants from the NIH (P01 NS092521, to MG, MK, DM, and IAA), to AT (F30NS100252), to MALR (K01HL133530), and to MK (R01HL094326 and R01NS100949); by the University of Chicago Medicine Comprehensive Cancer Center Support Grant (P30 CA14599), the William and Judith Davis Fund in Neurovascular Surgery Research, and the Safadi Translational Fellowship to RG; by the University of Chicago Pritzker School of Medicine to SL; by the Sigrid Juselius Foundation to JK; by a studentship from the National Sciences and Engineering Council to EC; and by the Canadian Institutes of Health Research to WBD (PJT 153000).

Address correspondence to: Issam A. Awad, Section of Neurosurgery, University of Chicago Medicine, 5841 S. Maryland, MC3026/Neurosurgery J341, Chicago, Illinois 60637, USA. Phone: 773.702.2123; Email: iawad@uchicago.edu.



1. Zeineddine HA, et al. Phenotypic characterization of murine models of cerebral cavernous malformations [published online ahead of print June 26, 2018]. *Lab Invest*. <https://doi.org/10.1038/s41374.018.0030-y>.
2. Shenkar R, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. *Genet Med*. 2015;17(3):188–196.
3. McDonald DA, et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. *Hum Mol Genet*. 2014;23(16):4357–4370.
4. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. *J Exp Med*. 2010;207(4):881–896.
5. Zhou Z, et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. *Nature*. 2016;532(7597):122–126.
6. Renz M. Regulation of  $\beta 1$  integrin-Klf2-mediated angiogenesis by CCM proteins. *Dev Cell*. 2015;32(2):181–190.
7. Girard R, et al. Plasma biomarkers of inflammation and angiogenesis predict cerebral cavernous malformation symptomatic hemorrhage or lesional growth. *Circ Res*. 2018;122(12):1716–1721.
8. Lopez-Ramirez MA, et al. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. *J Exp Med*. 2017;214(11):3331–3346.
9. Shi C, et al. B-cell depletion reduces the maturation of cerebral cavernous malformations in murine models. *J Neuroimmune Pharmacol*. 2016;11(2):369–377.
10. Shenkar R, et al. Differential gene expression in human cerebrovascular malformations. *Neurosurgery*. 2003;52(2):465–477.
11. Lin X, et al. The differentially expressed genes of human sporadic cerebral cavernous malformations. *World Neurosurg*. 2018;113:e247–e270.
12. Whitehead KJ, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. *Nat Med*. 2009;15(2):177–184.
13. Lant B, et al. Interrogating the ccm-3 Gene Network. *Cell Rep*. 2018;24(11):2857–2868.e4.
14. Lant B, et al. CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. *Nat Commun*. 2015;6:6449.
15. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. *J Biol Chem*. 1997;272(24):15442–15451.
16. Zhou HJ, et al. Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. *Nat Med*. 2016;22(9):1033–1042.
17. Jin M, et al. Toll-like receptor 2-mediated MAPKs and NF- $\kappa$ B activation requires the GNAO1-dependent pathway in human mast cells. *Integr Biol (Camb)*. 2016;8(9):968–975.
18. Garcia-Marcos M, Ghosh P, Farquhar MG. Molecular basis of a novel oncogenic mutation in GNAO1. *Oncogene*. 2011;30(23):2691–2696.
19. Berchtold MW, Villalobo A. The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. *Biochim Biophys Acta*. 2014;1843(2):398–435.
20. Wetzel-Strong SE, Detter MR, Marchuk DA. The pathobiology of vascular malformations: insights from human and model organism genetics. *J Pathol*. 2017;241(2):281–293.
21. Couto JA, et al. Endothelial cells from capillary malformations are enriched for somatic GNAQ mutations. *Plast Reconstr Surg*. 2016;137(1):77e–82e.
22. Shirley MD, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. *N Engl J Med*. 2013;368(21):1971–1979.
23. West XZ, et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. *Nature*. 2010;467(7318):972–976.
24. Tang AT, et al. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. *Nature*. 2017;545(7654):305–310.
25. Fistonich C, et al. Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development. *J Exp Med*. 2018;215(10):2586–2599.
26. Wang Y, et al. Plasma fibronectin supports hemostasis and regulates thrombosis. *J Clin Invest*. 2014;124(10):4281–4293.
27. Sadeqzadeh E, de Bock CE, Thorne RF. Sleeping giants: emerging roles for the fat cadherins in health and disease. *Med Res Rev*. 2014;34(1):190–221.
28. Glading AJ, Ginsberg MH. Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. *Dis Model Mech*. 2010;3(1-2):73–83.
29. Gagliardi F, Narayanan A, Mortini P. SPARCL1 a novel player in cancer biology. *Crit Rev Oncol Hematol*. 2017;109:63–68.
30. Liu W, et al. PLCD3, a flotillin2-interacting protein, is involved in proliferation, migration and invasion of nasopharyngeal carcinoma cells. *Oncol Rep*. 2018;39(1):45–52.
31. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. *J Mol Med*. 2008;86(7):785–789.
32. Gao G, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. *J Biol Chem*. 2002;277(11):9492–9497.
33. Hill KK, Bedian V, Juang JL, Hoffmann FM. Genetic interactions between the Drosophila Abelson (Abl) tyrosine kinase and failed axon connections (fax), a novel protein in axon bundles. *Genetics*. 1995;141(2):595–606.
34. Louvi A, Chen L, Two AM, Zhang H, Min W, Günel M. Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology. *Proc Natl Acad Sci U S A*. 2011;108(9):3737–3742.
35. Gupte RS, Pozarowski P, Grabarek J, Traganos F, Darzynkiewicz Z, Lee MY. R1alpha influences cellular proliferation in cancer cells by transporting RFC40 into the nucleus. *Cancer Biol Ther*. 2005;4(4):429–437.
36. Lee SY, Jang C, Lee KA. Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy. *Dev Reprod*. 2014;18(1):65–71.

37. Harel A, et al. Removal of a single pore subcomplex results in vertebrate nuclei devoid of nuclear pores. *Mol Cell*. 2003;11(4):853–864.
38. Guimaraes JC, Zavolan M. Patterns of ribosomal protein expression specify normal and malignant human cells. *Genome Biol*. 2016;17(1):236.
39. Jones DT, et al. Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. *Dis Model Mech*. 2013;6(1):115–124.
40. Liang X, Zhang L, Natarajan SK, Becker DF. Proline mechanisms of stress survival. *Antioxid Redox Signal*. 2013;19(9):998–1011.
41. Carlton JG, et al. Sorting nexin-2 is associated with tubular elements of the early endosome, but is not essential for retromer-mediated endosome-to-TGN transport. *J Cell Sci*. 2005;118(pt 19):4527–4539.
42. Jain A, Beutel O, Ebell K, Korneev S, Holthuis JC. Diverting CERT-mediated ceramide transport to mitochondria triggers Bax-dependent apoptosis. *J Cell Sci*. 2017;130(2):360–371.
43. Archer SL. Mitochondrial dynamics — mitochondrial fission and fusion in human diseases. *N Engl J Med*. 2013;369(23):2236–2251.
44. Ito S, Greiss S, Gartner A, Derry WB. Cell-nonautonomous regulation of *C. elegans* germ cell death by *kri-1*. *Curr Biol*. 2010;20(4):333–338.
45. Pal S, et al. CCM-3 promotes *C. elegans* germline development by regulating vesicle trafficking cytokinesis and polarity. *Curr Biol*. 2017;27(6):868–876.
46. Wang Y, et al. The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation [published online ahead of print September 25, 2018]. *FASEB J*. <https://doi.org/10.1096/fj.201800343R>.